A randomized, double‐blind, placebo‐controlled, phase II clinical trial to investigate the efficacy and safety of oral DA‐1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise-Reference-Cited by-同舟云学术

A randomized, double‐blind, placebo‐controlled, phase II clinical trial to investigate the efficacy and safety of oral DA‐1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise

Published:2014-12-05 Issue:3 Volume:31 Page:295-306
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Jung Chang Hee¹,Park Cheol‐Young²,Ahn Kyu‐Joeng³,Kim Nan‐Hee⁴,Jang Hak‐Chul⁵,Lee Moon‐Kyu⁶,Park Joong‐Yeol¹,Chung Choon‐Hee⁷,Min Kyung‐Wan⁸,Sung Yeon‐Ah⁹,Park Jeong‐Hyun¹⁰,Kim Sung Jin¹¹,Lee Hyo Jung¹¹,Park Sung‐Woo²

Affiliation:

1. Department of Internal Medicine, Asan Medical CenterUniversity of Ulsan College of Medicine Seoul Republic of Korea

2. Department of Internal Medicine, Kangbuk Samsung Medical CenterSungkyunkwan University School of Medicine Seoul Republic of Korea

3. Department of Internal MedicineGangdong Kyunghee University Hospital Seoul Republic of Korea

4. Department of Internal MedicineKorea University Ansan Hospital Seoul Republic of Korea

5. Department of Internal MedicineSeoul National University Bundang Hospital Seoul Republic of Korea

6. Department of Internal MedicineSamsung Medical Center Seoul Republic of Korea

7. Department of Internal MedicineYonsei University Wonju Severance Christian Hospital Wonju Republic of Korea

8. Department of Internal MedicineEulji Hospital Seoul Republic of Korea

9. Department of Internal MedicineEwha University Mokdong Hospital Seoul Republic of Korea

10. Department of Internal MedicineInje University Busan Paik Hospital Busan Republic of Korea

11. Clinical Development TeamDona‐A ST Seoul Republic of Korea

Funder

Dong-A ST Co., Ltd, Seoul, Republic of Korea

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.2613

Reference26 articles.

1. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

2. When Metformin Fails in Type 2 Diabetes Mellitus

3. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes

4. Linagliptin

5. Vildagliptin

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes;Journal of Diabetes Investigation;2024-04-27

2. Potential Therapeutic Targets for the management of Diabetes Mellitus Type 2;Current Medicinal Chemistry;2023-05-01

3. Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin;Diabetes, Obesity and Metabolism;2023-04-03

4. Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice;Experimental & Molecular Medicine;2023-04-03

5. Diabetes mellitus type-2: The panoramic view of potential therapeutic targets;THE FOURTH SCIENTIFIC CONFERENCE FOR ELECTRICAL ENGINEERING TECHNIQUES RESEARCH (EETR2022);2023